NES-ZIONA, Israel, Sept. 15 /PRNewswire-FirstCall/ -- Modigene Inc. (OTC Bulletin Board: MODG), a biopharmaceutical company applying its patented technology to develop longer-acting versions of already approved therapeutic proteins, today announced that President Shai Novik will present at the upcoming UBS Global Life Sciences Conference at 2:00 PM EDT on September 24, 2008.
The audio portion of the company's presentation will be webcast live. It can be accessed at the Investors section of the Modigene website at http://www.modigeneinc.com. An archived version of the webcast will be available for 30 days beginning three hours after the start of the presentation.
For more information about the UBS 2008 Global Life Sciences Conference, visit http://www.ibb.ubs.com.
Modigene Inc. is a biopharmaceutical company applying its patented CTP
technology to develop longer-acting, proprietary versions of already
approved therapeutic proteins that currently generate billions of dollars
in annual global sales. The CTP technology is applicable to virtually all
proteins, and Modigene is currently developing long-acting versions of
human growth hormone, interferon beta and erythropoietin, which are in late
preclinical development, as well as GLP-1. For more information on
Modigene, visit http://www.modigeneinc.com.
MODIGENE CONTACT: MEDIA CONTACT:
Shai Novik, President Barbara Lindheim
Modigene Inc. GendeLLindheim BioCom Partners
Tel: +1 866 644-7811 +1 212 918-4650
|SOURCE Modigene Inc.|
Copyright©2008 PR Newswire.
All rights reserved